# A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

> **NCT02251548** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 85 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Leukemia

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02251548
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-10
- **Primary completion:** 2025-01
- **Final completion:** 2027-01
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-10-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251548, "A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02251548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*